Product portfolio and pipeline

Henlius

Approved

Serplulimab [1] + **Chemo**
PD-1
ES-SCLC 1L

Serplulimab [1] + **Chemo** + **Radio**
PD-1
LS-SCLC 1L

Serplulimab [1] + **bevacizumab** + **Chemo**
PD-1+VEGF
mCRC 1L

HLX22

Serplulimab [1] + **HLX07**[15] (pimurutamab)
PD-1+EGFR
Solid tumors (sqNSCLC, etc.)

HLX07[15] (pimurutamab)
EGFR
Solid tumors (cSCC, etc.)

HLX43 [16]
PD-L1 ADC
Solid tumors (NSCLC, etc.)

HLX43 [16] + **Serplulimab** [1]
PD-L1 ADC + PD-1
Solid tumors

HLX87 [13] + **HLX22**[12] (dulpatatug)
HER2 ADC + HER2
BC 1L

HLX208[17]
BRAF V600E
Solid tumors

HLX6018
IPF

HLX701 [18]
RAS/BRAF wild-type mCRC

HLX37
PD-L1 x VEGF BsAb
Solid tumors

HLX3901
DLL3 x DLL3 x CD3 x CD28 TetraAb
SCLC, NEC

HLX17 (pembrolizumab)
PD-1
NSCLC, TNBC, etc.

HLX68
TL1A x IL23(p19) BsAb
IBD (UC、CD, etc.)

HLX320
TSHR x IGF1R BsAb
TED

Innovative mAb
Innovative fusion protein
Innovative multi-specific antibody
Innovative ADC
Small molecule
Biosimilar mAb

Bridging study in U.S.
BLA under FDA review
Global MRCT
Approved in global markets

(1) Approved in 50 countries and regions, including China, the UK, Germany, India, Singapore, trade name: Hetronifly® in Europe. Business partners: KGbio/ Fosun Pharma/ Intas/ Lotus/ Abbott/ Eisai.

(2) Approved in China and multiple Latin American countries. The first biosimilar approved in China. Business partners: Fosun Pharma/ Eurofarma/ Abbott/ Boston Oncology.

(3) The first rituximab approved for the indication in China.

(4) Approved in 50+ countries, including China, U.S., the UK, Germany, France and Australia, trade name in U.S.: HERCESSI™. Trade name in Europe: Zercepac®. Business partners: Accord/ Elea/ Eurofarma/ Abbott/ KGbio/ Getz Pharma.

(5) Business partners: Fosun Wanbang/ Getz Pharma.

(6) Approved in China and multiple Latin American countries. Business partners: Eurofarma.

(7) Approved in North America and Europe, Business partner: Organon. Trade name: BILDYOS® (60mg/mL), BILPREVDA® (120mg/1.7mL) in the U.S. and Europe. Marketing applications are under review in China.

(8) Approved in China, the U.S. and Europe. Trade name: POHERDY® in the U.S. and Europe. Business partner: Organon.

(9) Commercialization in China.

(10) NDA under review in China. Business partner: Essex.

(11) Exclusive commercialisation rights and development rights in Chinese Mainland and Macau

(12) IND approvals obtained in China/ the U.S./ Japan/ the EU

(13) The development and exclusive commercialization rights obtained in China and select ex-China markets.

(14) Exclusive license obtained in China. Phase 3 MRCT enrolling globally. IND approval obtained in China.

(15) IND approvals obtained in China/the U.S.

(16) IND approvals obtained in China/ the U.S./ Japan/ Australia/ Europe.

(17) Exclusive license obtained in China.

(18) Exclusive rights in China (excl. Taiwan), several countries in Southeast Asia, and other selected countries and regions; Phase 1b/2a conducting in countries such as China and the U.S.

(19) IND approvals obtained in China/the U.S. Business partner: Dr. Reddy's, etc.

(20) Business partner: Sandoz, etc.

Last update: October 08, 2026

©Copyright Henlius 2026.